PCSA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Processa Pharmaceuticals Inc (PCSA) is not a strong buy at the moment for a beginner investor with a long-term focus. The lack of positive financial performance, absence of significant trading trends, and no clear technical or proprietary trading signals suggest that this stock does not present a compelling investment opportunity right now.
The MACD is slightly positive but contracting, RSI is neutral at 54.96, and moving averages are converging, indicating no strong trend. Key support is at 2.743, and resistance is at 3.312. The stock has a 60% chance of minor movements in the short term, with no clear upward momentum.
NULL identified. No recent news or significant insider or hedge fund activity.
Financial performance is weak, with negative net income and EPS dropping significantly (-92.34% YoY). No recent trading activity from Congress or influential figures.
In Q4 2025, revenue remained at 0 with no growth. Net income improved slightly to -$3,358,938 (up 23.10% YoY), but EPS dropped significantly to -1.49 (-92.34% YoY). Gross margin remains at 0.
No analyst rating or price target data available.
